JPJinbum Park

Jinbum Park

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinbum Park has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ginsenoside Rh2 Enhances CD8+ T Cell-Mediated Anticancer Immunity in Hepatocellular Carcinoma

    by Jinbum Park, Inae Jeong, Anna Han, Ok-Kyung Kim

    Background: Ginsenoside Rh2 (Rh2), a bioactive metabolite of Panax ginseng, has documented anticancer effects, but its role in cancer–immune crosstalk remains incompletely defined. Thus, we aimed to investigate the role of Rh2 in hepatocellular carcinoma (HCC) cells and immune regulation. Methods: We used a co-culture system of murine Hepa1-6 hepatocellular carcinoma cells or nonmalignant AML12 hepatocytes with primary splenocytes to model cancer–immune interactions during Rh2 exposure. Readouts included cell viability, nuclear morphology, and multiparameter flow cytometry. Results: In a co-culture system of Hepa1-6 cells and splenocytes, Rh2 decreased bulk cell viability and increased apoptosis in Hepa1-6 cells. CD8+ T cells exhibited enhanced effector features, with increased CD107a and IFN-γ expression following Rh2 treatment. Rh2 reduced PD-L1 expression on Hepa1-6 cells and splenocytes, and PD-1 expression on CD8+ T cells. Rh2 also reduced TGF-β1 and IL-6 levels in both Hepa1-6 cells and splenocytes, and decreased IL-10 levels in splenocytes. This was accompanied by a reduction in CD4+CD25+FOXP3+ regulatory T cells (Tregs). Conclusions: In a physiologically relevant cancer–immune context, Rh2 reprograms suppressive interactions by enhancing CD8+ T cell effector function, dampening PD-L1/PD-1 signaling, and reducing key immunosuppressive cytokines and Tregs. These coordinated effects position Rh2 as a candidate multi-target immunomodulatory agent for enhancing anticancer immunity.


  • Open Access

    Salmon Nasal Cartilage-Derived Proteoglycans Alleviate Monosodium Iodoacetate-Induced Osteoarthritis in Rats

    by Inae Jeong, Jinbum Park, Shinjung Park, Tatuya Wada, Dae Soo Lim, Ok-Kyung Kim

    Osteoarthritis is a chronic inflammatory condition characterized by the degeneration of joint cartilage and underlying bone, resulting in pain, swelling, and reduced mobility. This study evaluates the efficacy of salmon nasal cartilage-derived proteoglycans in mitigating osteoarthritis symptoms and investigates the underlying molecular mechanisms. This study employed a rat model of osteoarthritis induced by monosodium iodoacetate (MIA) injection. The rats were orally administered salmon nasal cartilage-derived proteoglycans or ibuprofen. Key aspects of osteoarthritis pathology, including impaired exercise ability, inflammation, extracellular matrix degradation, and chondrocyte apoptosis, were assessed using histological analysis, micro-CT, treadmill testing, serum assays, and mRNA/protein expression studies. The MIA injection caused significant cartilage damage, reduced bone mineral density, and impaired exercise ability. Additionally, it elevated serum levels of prostaglandin E2 and nitric oxide, increased the mRNA and protein levels of inflammation-related factors, and activated apoptosis signaling pathways in cartilage. Treatment with salmon nasal cartilage-derived proteoglycans significantly improved cartilage morphology and mineralization, reduced inflammation, and inhibited apoptosis signaling pathways, with effects comparable to those observed with ibuprofen treatment. These findings highlight the potential of salmon nasal cartilage-derived proteoglycans as a therapeutic agent for managing osteoarthritis by effectively reducing inflammation, preventing cartilage degradation, and inhibiting chondrocyte apoptosis.